Iris M. C. van der Ploeg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iris M. C. van der Ploeg has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Omgo E. Nieweg
Antoni van Leeuwenhoek Hospital
13 shared publicationsBin B. R. Kroon
Antoni van Leeuwenhoek Hospital
12 shared publicationsRenato A. Valdés Olmos
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
12 shared publicationsEmiel J. T. Rutgers
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
5 shared publicationsJan Paul de Boer
Departments of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands
4 shared publicationsAriane A. van Loevezijn
Department of Surgical Oncology, Netherlands Cancer Institute–Antoni van Leeuwenhoek, Amsterdam, The Netherlands
3 shared publications
Latest Publications
- 1 May 2026
- Published by Springer Nature
- p. 175-189
Localisation Using Iodine Seeds
- 5 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (4) , 3410-3411
ASO Visual Abstract: The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate Our Former Strategy? Reevaluating the Role of Internal Mammary Sentinel Node Removal in Breast Cancer Surgery
- 5 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (4) , 3410-3411
ASO Visual Abstract: The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate Our Former Strategy? Reevaluating the Role of Internal Mammary Sentinel Node Removal in Breast Cancer Surgery
- Open Access
- 30 January 2026
- Published by Springer Nature in Breast Cancer Research
- Vol. 28 (1)
One size does not fit all: data-driven insights of patient-reported outcomes to tailor supportive care in breast cancer
Supportive care resources are limited, requiring a strategic, tailored approach, especially with the growing population of breast cancer patients. We exami
- 30 January 2026
- Published by Springer Nature in Breast Cancer Research
- Vol. 28 (1)
Open AccessOne size does not fit all: data-driven insights of patient-reported outcomes to tailor supportive care in breast cancer
Supportive care resources are limited, requiring a strategic, tailored approach, especially with the growing population of breast cancer patients. We exami
- 5 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (4) , 3345-3354
The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate our Former Strategy?
The clinical significance of internal mammary chain sentinel lymph nodes (IMCSNs) remains debated, with no consensus on the diagnostic and prognostic value
- 5 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (4) , 3345-3354
The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate our Former Strategy?
The clinical significance of internal mammary chain sentinel lymph nodes (IMCSNs) remains debated, with no consensus on the diagnostic and prognostic value
- 24 July 2025
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 46 (11) , 1043-1051
Malignancy classification of thyroid incidentalomas using 18F-fluorodeoxy-d-glucose PET/computed tomography-derived radiomics
Background: Thyroid incidentalomas (TIs) are incidental thyroid lesions detected on fluorodeoxy-d-glucose (18F-FDG) PET/computed tomography (PET/CT) scans. This study aims to investigate the role of noninvasive PET/CT-derived radiomic features in characterizing 18F-FDG PET/CT TIs and distinguishing benign from malignant thyroid lesions in oncological patients. Materials and methods: We included 46 patients with PET/CT TIs who underwent thyroid ultrasound and thyroid surgery at our oncological referral hospital. Radiomic features extracted from regions of interest (ROI) in both PET and CT images and analyzed for their association with thyroid cancer and their predictive ability. The TIs were graded using the ultrasound TIRADS classification, and histopathological results served as the reference standard. Univariate and multivariate analyses were performed using features from each modality individually and combined. The performance of radiomic features was compared to the TIRADS classification. Results: Among the 46 included patients, 36 patients (78%) had malignant thyroid lesions, while 10 patients (22%) had benign lesions. The combined run length nonuniformity radiomic feature from PET and CT cubical ROIs demonstrated the highest area under the curve (AUC) of 0.88 (P < 0.05), with a negative correlation with malignancy. This performance was comparable to the TIRADS classification (AUC: 0.84, P < 0.05), which showed a positive correlation with thyroid cancer. Multivariate analysis showed higher predictive performance using CT-derived radiomics (AUC: 0.86 ± 0.13) compared to TIRADS (AUC: 0.80 ± 0.08). Conclusion: This study highlights the potential of 18F-FDG PET/CT-derived radiomics to distinguish benign from malignant thyroid lesions. Further studies with larger cohorts and deep learning-based methods could obtain more robust results.
- 24 July 2025
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 46 (11) , 1043-1051
Malignancy classification of thyroid incidentalomas using 18F-fluorodeoxy-d-glucose PET/computed tomography-derived radiomics
Background: Thyroid incidentalomas (TIs) are incidental thyroid lesions detected on fluorodeoxy-d-glucose (18F-FDG) PET/computed tomography (PET/CT) scans. This study aims to investigate the role of noninvasive PET/CT-derived radiomic features in characterizing 18F-FDG PET/CT TIs and distinguishing benign from malignant thyroid lesions in oncological patients. Materials and methods: We included 46 patients with PET/CT TIs who underwent thyroid ultrasound and thyroid surgery at our oncological referral hospital. Radiomic features extracted from regions of interest (ROI) in both PET and CT images and analyzed for their association with thyroid cancer and their predictive ability. The TIs were graded using the ultrasound TIRADS classification, and histopathological results served as the reference standard. Univariate and multivariate analyses were performed using features from each modality individually and combined. The performance of radiomic features was compared to the TIRADS classification. Results: Among the 46 included patients, 36 patients (78%) had malignant thyroid lesions, while 10 patients (22%) had benign lesions. The combined run length nonuniformity radiomic feature from PET and CT cubical ROIs demonstrated the highest area under the curve (AUC) of 0.88 (P < 0.05), with a negative correlation with malignancy. This performance was comparable to the TIRADS classification (AUC: 0.84, P < 0.05), which showed a positive correlation with thyroid cancer. Multivariate analysis showed higher predictive performance using CT-derived radiomics (AUC: 0.86 ± 0.13) compared to TIRADS (AUC: 0.80 ± 0.08). Conclusion: This study highlights the potential of 18F-FDG PET/CT-derived radiomics to distinguish benign from malignant thyroid lesions. Further studies with larger cohorts and deep learning-based methods could obtain more robust results.
- Open Access
- 29 January 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (3) , 035010
Assessing fetal radiation dose from iodine-125 seeds in pregnant breast cancer patients: an updated model
Objective. The treatment of breast cancer during pregnancy requires careful consideration of consequences for both maternal and fetal health. In non-pregnant patients, the use of radioactive iodine-125 (125I)-seeds is standard practice for localising non-palpable breast tumors before breast-conserving surgery. However, the use of 125I-seeds in pregnant patients has been avoided due to concerns about fetal radiation exposure. Approach. In this study a mathematical model was developed to estimate the fetal absorbed dose based on several factors: the radioactivity of the 125I-seed, the duration of implantation, and the distance between the 125I-seed and fetus as a function of maternal anatomy, gestational age, and fetal development. Three scenarios, representing a range of maternal and fetal anatomy, were evaluated, including a worst-case scenario from a radiation safety perspective. Main results. The results show that the fetal absorbed dose varies across the three scenarios, with ranges of 0.0–0.4 mGy, 0.0–1.0 mGy, and 0.0–1.6 mGy, depending on when the 125I-seed was implanted and when it was removed. These dose ranges are similar to conventional diagnostic x-ray scans. The maximum calculated absorbed dose (1.6 mGy) is unlikely to be reached in practice and is well below the 100 mGy threshold associated with possible fetal malformations. The associated theoretical cancer risk increase (0.016%) is minimal. Significance. The use of 125I-seeds as localisation method of breast tumors in pregnant patients results in low fetal radiation doses and should not be avoided due to dose concerns.
- 29 January 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (3) , 035010
Open AccessAssessing fetal radiation dose from iodine-125 seeds in pregnant breast cancer patients: an updated model
Objective. The treatment of breast cancer during pregnancy requires careful consideration of consequences for both maternal and fetal health. In non-pregnant patients, the use of radioactive iodine-125 (125I)-seeds is standard practice for localising non-palpable breast tumors before breast-conserving surgery. However, the use of 125I-seeds in pregnant patients has been avoided due to concerns about fetal radiation exposure. Approach. In this study a mathematical model was developed to estimate the fetal absorbed dose based on several factors: the radioactivity of the 125I-seed, the duration of implantation, and the distance between the 125I-seed and fetus as a function of maternal anatomy, gestational age, and fetal development. Three scenarios, representing a range of maternal and fetal anatomy, were evaluated, including a worst-case scenario from a radiation safety perspective. Main results. The results show that the fetal absorbed dose varies across the three scenarios, with ranges of 0.0–0.4 mGy, 0.0–1.0 mGy, and 0.0–1.6 mGy, depending on when the 125I-seed was implanted and when it was removed. These dose ranges are similar to conventional diagnostic x-ray scans. The maximum calculated absorbed dose (1.6 mGy) is unlikely to be reached in practice and is well below the 100 mGy threshold associated with possible fetal malformations. The associated theoretical cancer risk increase (0.016%) is minimal. Significance. The use of 125I-seeds as localisation method of breast tumors in pregnant patients results in low fetal radiation doses and should not be avoided due to dose concerns.
- Open Access
- 25 September 2024
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 20 (2) , 465-482
“Numbers call for action, personalized narratives provide support and recognition”: a qualitative assessment of cancer patients’ perspectives on patient-reported outcome measures (PROMs) feedback with narratives
Purpose Patient-reported outcome measures (PROMs) are questionnaires completed by patients to gain insight in their health-related quality of life. However, patients often find the interpretation of PROMS challenging. A personalized narrative, i.e., a story with patients’ experiences tailored to the reader, could help explain PROMs and might be appreciated alongside numerical outcomes. We studied how cancer patients perceive PROMs feedback presented in a regular numerical and a novel narrative format. Methods Cancer patients who completed PROMs in routine clinical practice were recruited. All participants received numerical feedback and a personalized narrative. Semi-structured interviews were conducted to uncover perceptions of both formats. Interviews were analyzed with an inductive reflexive approach to thematic analysis. Results Twenty-nine patients with breast cancer, melanoma, and bladder cancer participated. Thematic analysis identified six themes: “Understanding: I get the gist of it!”; “Usefulness: Tell me why I should complete PROMs”; “Format preferences: Numbers are cold, narratives are warm”; “Taking action: Can I do something about my score?”; “Personal relevance: Personalized narratives show me what life has in store for me”; and “Personal relevance: That’s (not) me!” Numbers seemed to help participants act, whereas narratives may provide emotional support and recognition. Participants identified with the content of the narrative yet differed in how they related to the main character. Conclusion Personalized narratives could be a useful addition to PROMs feedback. The studied formats seem to serve different purposes; numbers help to facilitate action, personalized narratives provide recognition. Implications for Cancer Survivors Personalized narratives may be a useful new way to communicate about quality of life to cancer survivors and help them to envision what the impact of cancer can be.
- 25 September 2024
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 20 (2) , 465-482
Open Access“Numbers call for action, personalized narratives provide support and recognition”: a qualitative assessment of cancer patients’ perspectives on patient-reported outcome measures (PROMs) feedback with narratives
Purpose Patient-reported outcome measures (PROMs) are questionnaires completed by patients to gain insight in their health-related quality of life. However, patients often find the interpretation of PROMS challenging. A personalized narrative, i.e., a story with patients’ experiences tailored to the reader, could help explain PROMs and might be appreciated alongside numerical outcomes. We studied how cancer patients perceive PROMs feedback presented in a regular numerical and a novel narrative format. Methods Cancer patients who completed PROMs in routine clinical practice were recruited. All participants received numerical feedback and a personalized narrative. Semi-structured interviews were conducted to uncover perceptions of both formats. Interviews were analyzed with an inductive reflexive approach to thematic analysis. Results Twenty-nine patients with breast cancer, melanoma, and bladder cancer participated. Thematic analysis identified six themes: “Understanding: I get the gist of it!”; “Usefulness: Tell me why I should complete PROMs”; “Format preferences: Numbers are cold, narratives are warm”; “Taking action: Can I do something about my score?”; “Personal relevance: Personalized narratives show me what life has in store for me”; and “Personal relevance: That’s (not) me!” Numbers seemed to help participants act, whereas narratives may provide emotional support and recognition. Participants identified with the content of the narrative yet differed in how they related to the main character. Conclusion Personalized narratives could be a useful addition to PROMs feedback. The studied formats seem to serve different purposes; numbers help to facilitate action, personalized narratives provide recognition. Implications for Cancer Survivors Personalized narratives may be a useful new way to communicate about quality of life to cancer survivors and help them to envision what the impact of cancer can be.
- Open Access
- 12 June 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 206 (3) , 585-594
Clinical implications of non-breast cancer related findings on FDG-PET/CT scan prior to neoadjuvant chemotherapy in patients with breast cancer
Purpose: Breast cancer (BC) patients undergoing FDG-PET/CT scans for neoadjuvant chemotherapy (NAC) may have additional non-BC related findings. The aim of this study is to describe the clinical implications of these findings. Methods: We included BC patients who underwent an FDG-PET/CT scan in our institute between 2011–2020 prior to NAC. We focused on patients with an additional non-BC related finding (i.e. BC metastases were excluded) for which diagnostic work-up was performed. Information about the diagnostic work-up and the clinical consequences was retrospectively gathered. A revision of all FDG-PET/CT scans was conducted by an independent physician to assess the suspicion level of the additional findings. Results: Of the 1337 patients who underwent FDG-PET/CT, 202 patients (15%) had an non-BC related additional finding for which diagnostic work-up was conducted, resulting in 318 examinations during the first year. The non-BC related findings were mostly detected in the endocrine region (26%), gastro-intestinal region (16%), or the lungs (15%). Seventeen patients (17/202: 8%, 17/1337: 1.3%) had a second primary malignancy. Only 8 patients (8/202: 4%, 8/1337: 0.6%) had a finding that was considered more prognosis-determining than their BC disease. When revising all FDG-PET/CT scans, 57 (202/57: 28%) of the patients had an additional finding categorized as low suspicious, suggesting no indication for diagnostic work-up. Conclusion: FDG-PET/CT scans used for dissemination imaging in BC patients detect a high number of non-BC related additional findings, often clinically irrelevant and causing a large amount of unnecessary work-up. However, in 8% of the patients undergoing diagnostic work-up for an additional finding, a second primary malignancy was detected, warranting diagnostic attention in selected patients.
- 12 June 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 206 (3) , 585-594
Open AccessClinical implications of non-breast cancer related findings on FDG-PET/CT scan prior to neoadjuvant chemotherapy in patients with breast cancer
Purpose: Breast cancer (BC) patients undergoing FDG-PET/CT scans for neoadjuvant chemotherapy (NAC) may have additional non-BC related findings. The aim of this study is to describe the clinical implications of these findings. Methods: We included BC patients who underwent an FDG-PET/CT scan in our institute between 2011–2020 prior to NAC. We focused on patients with an additional non-BC related finding (i.e. BC metastases were excluded) for which diagnostic work-up was performed. Information about the diagnostic work-up and the clinical consequences was retrospectively gathered. A revision of all FDG-PET/CT scans was conducted by an independent physician to assess the suspicion level of the additional findings. Results: Of the 1337 patients who underwent FDG-PET/CT, 202 patients (15%) had an non-BC related additional finding for which diagnostic work-up was conducted, resulting in 318 examinations during the first year. The non-BC related findings were mostly detected in the endocrine region (26%), gastro-intestinal region (16%), or the lungs (15%). Seventeen patients (17/202: 8%, 17/1337: 1.3%) had a second primary malignancy. Only 8 patients (8/202: 4%, 8/1337: 0.6%) had a finding that was considered more prognosis-determining than their BC disease. When revising all FDG-PET/CT scans, 57 (202/57: 28%) of the patients had an additional finding categorized as low suspicious, suggesting no indication for diagnostic work-up. Conclusion: FDG-PET/CT scans used for dissemination imaging in BC patients detect a high number of non-BC related additional findings, often clinically irrelevant and causing a large amount of unnecessary work-up. However, in 8% of the patients undergoing diagnostic work-up for an additional finding, a second primary malignancy was detected, warranting diagnostic attention in selected patients.
- 8 January 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 204 (3) , 497-507
Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome
Introduction Breast cancer patients with invasive lobular carcinoma (ILC) have an increased risk of positive margins after surgery and often show little response to neoadjuvant chemotherapy (NAC). We aimed to investigate surgical outcomes in patients with ILC treated with NAC. Methods In this retrospective cohort study, all breast cancer patients with ILC treated with NAC who underwent surgery at the Netherlands Cancer Institute from 2010 to 2019 were selected. Patients with mixed type ILC in pre-NAC biopsies were excluded if the lobular component was not confirmed in the surgical specimen. Main outcomes were tumor-positive margins and re-excision rate. Associations between baseline characteristics and tumor-positive margins were assessed, as were complications, locoregional recurrence rate (LRR), recurrence-free survival (RFS), and overall survival (OS). Results We included 191 patients. After NAC, 107 (56%) patients had breast conserving surgery (BCS) and 84 (44%) patients underwent mastectomy. Tumor-positive margins were observed in 67 (35%) patients. Fifty five (51%) had BCS and 12 (14%) underwent mastectomy (p value < 0.001). Re-excision was performed in 35 (33%) patients with BCS and in 4 (5%) patients with mastectomy. Definitive surgery was mastectomy in 107 (56%) patients and BCS in 84 (44%) patients. Tumor-positive margins were associated with cT ≥ 3 status (OR 4.62, 95% CI 1.26–16.98, p value 0.021) in the BCS group. Five-year LRR (4.7%), RFS (81%), and OS (93%) were not affected by type of surgery after NAC. Conclusion Although 33% of ILC breast cancer patients undergoing BCS after NAC required re-excision for positive resection margins, it is considered safe given that five-year RFS remained excellent and LRR and OS did not differ by extent of surgery.
- 8 January 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 204 (3) , 497-507
Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome
Introduction Breast cancer patients with invasive lobular carcinoma (ILC) have an increased risk of positive margins after surgery and often show little response to neoadjuvant chemotherapy (NAC). We aimed to investigate surgical outcomes in patients with ILC treated with NAC. Methods In this retrospective cohort study, all breast cancer patients with ILC treated with NAC who underwent surgery at the Netherlands Cancer Institute from 2010 to 2019 were selected. Patients with mixed type ILC in pre-NAC biopsies were excluded if the lobular component was not confirmed in the surgical specimen. Main outcomes were tumor-positive margins and re-excision rate. Associations between baseline characteristics and tumor-positive margins were assessed, as were complications, locoregional recurrence rate (LRR), recurrence-free survival (RFS), and overall survival (OS). Results We included 191 patients. After NAC, 107 (56%) patients had breast conserving surgery (BCS) and 84 (44%) patients underwent mastectomy. Tumor-positive margins were observed in 67 (35%) patients. Fifty five (51%) had BCS and 12 (14%) underwent mastectomy (p value < 0.001). Re-excision was performed in 35 (33%) patients with BCS and in 4 (5%) patients with mastectomy. Definitive surgery was mastectomy in 107 (56%) patients and BCS in 84 (44%) patients. Tumor-positive margins were associated with cT ≥ 3 status (OR 4.62, 95% CI 1.26–16.98, p value 0.021) in the BCS group. Five-year LRR (4.7%), RFS (81%), and OS (93%) were not affected by type of surgery after NAC. Conclusion Although 33% of ILC breast cancer patients undergoing BCS after NAC required re-excision for positive resection margins, it is considered safe given that five-year RFS remained excellent and LRR and OS did not differ by extent of surgery.
- Open Access
The Safe Use of 125I-Seeds as a Localization Technique in Breast Cancer during Pregnancy
Introduction: Some aspects of the treatment protocol for breast cancer during pregnancy (PrBC) have not been thoroughly studied. This study provides clarity regarding the safety of the use of 125I-seeds as a localization technique for breast-conserving surgery in patients with PrBC. Methods: To calculate the exposure to the fetus of one 125I-seed implanted in a breast tumor, we developed a model accounting for the decaying 125I-source, time to surgery, and the declining distance between the 125I-seed and the fetus. The primary outcome was the maximum cumulative fetal dose of radiation at consecutive gestational ages (GA). Results: The cumulative fetal dose remains below 1 mSv if a single 125I-seed is implanted at a GA of 26 weeks. After a GA of 26 weeks, the fetal dose can be at a maximum of 11.6 mSv. If surgery takes place within two weeks of implantation from a GA of 26 weeks, and one week above a GA of 32 weeks, the dose remains below 1 mSv. Conclusion: The use of 125I-seeds is safe in PrBC. The maximum fetal exposure remains well below the threshold of 100 mSv, and therefore, does not lead to an increased risk of fetal tissue damage. Still, we propose keeping the fetal dose as low as possible, preferably below 1 mSv.
Open AccessThe Safe Use of 125I-Seeds as a Localization Technique in Breast Cancer during Pregnancy
Introduction: Some aspects of the treatment protocol for breast cancer during pregnancy (PrBC) have not been thoroughly studied. This study provides clarity regarding the safety of the use of 125I-seeds as a localization technique for breast-conserving surgery in patients with PrBC. Methods: To calculate the exposure to the fetus of one 125I-seed implanted in a breast tumor, we developed a model accounting for the decaying 125I-source, time to surgery, and the declining distance between the 125I-seed and the fetus. The primary outcome was the maximum cumulative fetal dose of radiation at consecutive gestational ages (GA). Results: The cumulative fetal dose remains below 1 mSv if a single 125I-seed is implanted at a GA of 26 weeks. After a GA of 26 weeks, the fetal dose can be at a maximum of 11.6 mSv. If surgery takes place within two weeks of implantation from a GA of 26 weeks, and one week above a GA of 32 weeks, the dose remains below 1 mSv. Conclusion: The use of 125I-seeds is safe in PrBC. The maximum fetal exposure remains well below the threshold of 100 mSv, and therefore, does not lead to an increased risk of fetal tissue damage. Still, we propose keeping the fetal dose as low as possible, preferably below 1 mSv.